1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Biocartis Group NV
  6. Company
    BCART   BE0974281132

BIOCARTIS GROUP NV

(BCART)
  Report
Real-time Euronext Bruxelles  -  11:35 2022-08-05 am EDT
1.718 EUR   +2.14%
06/22ADRs End Lower; ArcelorMittal, AstraZeneca Trade Actively
DJ
06/22Biocartis, AstraZeneca To Jointly Develop Companion Lung Cancer Diagnostic Test For Tagrisso
MT
06/22PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Biocartis Group NV
Biocartis Group NV specializes in the development of molecular diagnostic systems. Especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.

Net sales by source of income are mainly distributed between products sales (83.9%) and sale of collaboration services (16.1%; especially research and development services).

Number of employees : 619 people.
Sales per Business
20202021Delta
Cartridge24.8157.5%31.6265.5% +27.45%
Research & Development Services8.1819%5.8712.2% -28.23%
Idylla System4.3910.2%5.0510.5% +15.03%
Idylla System Rental2.706.3%3.827.9% +41.63%
Idylla System Service1.252.9%1.733.6% +38.84%
License Fees1.814.2%0.190.4% -89.8%
EUR in Million
Sales per region
20202021Delta
Rest of the World11.7727.3%15.8632.9% +34.75%
United States15.6036.2%10.9722.7% -29.72%
Great Britain3.979.2%7.9416.4% +99.85%
France3.508.1%4.328.9% +23.53%
Germany2.956.8%3.637.5% +23.05%
Spain2.876.6%3.457.2% +20.45%
China1.994.6%1.493.1% -25.19%
Belgium0.481.1%0.621.3% +28.48%
EUR in Million
Managers
Name Title Age Since
Herman Verrelst Chief Executive Officer 48 2017
Jean-Marc Roelandt Chief Financial Officer 56 -
Benoit Devogelaere, Dr. Chief Technology Officer 41 2011
Piet Houwen Chief Operating Officer 53 -
Renate Degrave Head-Corporate Communications & IR - 2019
Susy Spruyt Head-People & Organization 53 -
Members of the board
Name Title Age Since
Christian Reinaudo, Dr. Independent Chairman 67 2018
Ann-Christine Sundell Independent Director 57 2018
Luc Gijsens Independent Director 68 2018
Christine D. Kuslich, Dr. Independent Director - -
Roald Borré Non-Executive Director 49 2014
Herman Verrelst Chief Executive Officer 48 2017
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 57,545,663 49,834,544 86.6% 0 0.0% 86.6%
Shareholders
NameEquities%
Invesco Advisers, Inc. 6,963,025 12.1%
Johnson & Johnson 5,481,128 9.52%
Participatiemaatschappij Vlaanderen NV 2,244,280 3.90%
Credit Suisse Asset Management (Schweiz) AG 2,140,410 3.72%
Credit Suisse Group AG 1,841,461 3.20%
Mirova SA (Investment Management) 882,561 1.53%
KBC Asset Management NV 516,061 0.90%
Tocqueville Finance SA 447,272 0.78%
BNP Paribas Asset Management Belgium SA 340,514 0.59%
Invesco Asset Management Ltd. 292,730 0.51%
Markets and indexes
- Compartiment B
- BEL Small / PEA
Stock Exchange Codes
- Bloomberg Code :  BCART:BE
- Reuters Code :  BCART.BR
- Datastream Code :  
Company contact information
Biocartis Group NV
Generaal De Wittelaan 11B
BE-2800 Mechelen, Antwerpen

Phone : +32 15 632 600
Fax :
web site : https://investors.biocartis.com/en
Brand Portfolio
In partnership withAllbrands.markets
More brands of Biocartis Group NV